Results 31 to 40 of about 13,097,347 (378)

Black and white teas as potential agents to combine with amphotericin B and protect red blood cells from amphotericin B-mediated toxicity

Brazilian Journal of Biology, 2018
Amphotericin B is a fungicidal substance that is treatment of choice for most systemic fungal infections affecting immunocompromised patients. However, severe side effects have limited the utility of this drug.
V. M. Oliveira, N. M. Khalil, E. Carraro
doaj   +1 more source

Do Ophthalmic Solutions of Amphotericin B Solubilised in 2-Hydroxypropyl-γ-Cyclodextrins Possess an Extended Physicochemical Stability?

Pharmaceutics, 2020
Fungal keratitis is a sight-threatening disease for which amphotericin B eye drops is one of the front-line treatments. Unfortunately, there are currently no commercial forms available, and there is little data concerning the long-term stability of ...
Philip Chennell, Mouloud Yessaad, Florence Abd El Kader, Mireille Jouannet, Mathieu Wasiak, Yassine Bouattour, Valérie Sautou   +6 more
doaj   +1 more source

Combination Antifungal Therapy for Cryptococcal Meningitis [PDF]

, 2013
Background Combination antifungal therapy (amphotericin B deoxycholate and flucytosine) is the recommended treatment for cryptococcal meningitis but has not been shown to reduce mortality, as compared with amphotericin B alone. We performed a randomized,
Baker, Stephen G., Campbell, James I., Chau, Nguyen V.V., Chau, Tran T.H., Chuong, Ly V., Day, Jeremy N., Diep, Pham T., Dung, Nguyen T., Duong, Van A., Farrar, Jeremy J., Hien, Tran T., Hoang, Thu N., Lalloo, David, Mai, Nguyen H., Mai, Pham P., Nghia, Ho D., Phong, Nguyen D., Phu, Nguyen H., Sieu, Tran P.M., Sinh, Dinh X., Thai, Cao Q., Thai, Le H., Wolbers, Marcel   +22 more
core   +1 more source

In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against Candida auris

Pharmaceutics, 2021
Treatment of invasive infections caused by Candida auris is challenging due to the limited therapeutic options. The combination of antifungal drugs may be an interesting and feasible approach to be investigated.
Unai Caballero, Elena Eraso, Guillermo Quindós, Nerea Jauregizar   +3 more
doaj   +1 more source

Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study [PDF]

, 1999
Background: Treatment of invasive aspergillosis is frequently unsuccessful, so innovations in therapy are needed. Clinical studies demonstrate that itraconazole may be an effective alternative to amphotericin B.
Armstrong, Donald, Popp, Adrian I., Quadri, Tariq, Walshe, Louise, White, Mary H.   +4 more
core   +1 more source

Liposomal amphotericin B—the present

Journal of Antimicrobial Chemotherapy, 2022
AbstractMost invasive fungal infections are opportunistic in nature but the epidemiology is constantly changing, with new risk groups being identified. Neutropenia is a classical risk factor for fungal infections, while critically ill patients in the ICU are now increasingly at risk of yeast and mould infections.
Maertens J., Pagano L., Azoulay E., Warris A.   +3 more
openaire   +3 more sources

Limited Activity Of Miltefosine In Murine Models Of Cryptococcal Meningoencephalitis And Disseminated Cryptococcosis [PDF]

, 2013
Miltefosine is an alkyl phosphocholine with good oral bioavailability and in vitro activity against Cryptococcus species that has gained interest as an additional agent for cryptococcal infections.
Bocanegra, Rosie, Kirkpatrick, William R., Najvar, Laura K., Patterson, Thomas F., Sorrell, Tania C., Wiederhold, Nathan P.   +5 more
core   +1 more source

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

New England Journal of Medicine, 2002
BACKGROUND Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis.
R. Herbrecht, D. Denning, T. Patterson, J. Bennett, R. Greene, J. Oestmann, W. Kern, K. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. Rubin, J. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. Chandrasekar, M. Hodges, H. Schlamm, P. Troke, B. D. de Pauw   +21 more
semanticscholar   +1 more source

Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. [PDF]

, 2011
Due to unacceptably high mortality with pentavalent antimonials, Médecins Sans Frontières in 2006 began using liposomal amphotericin B (AmBisome) for visceral leishmaniasis (VL) patients in Ethiopia who were severely ill or positive for human ...
Aderie, Endashaw Mengistu, Chane, Solomon, Collin, Simon M, Davidson, Robert N, Piening, Turid, Ritmeijer, Koert, ter Horst, Rachel   +6 more
core   +2 more sources

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B

Clinical Infectious Diseases, 2019
Since its introduction in the 1990s, liposomal amphotericin B (LAmB) continues to be an important agent for the treatment of invasive fungal diseases caused by a wide variety of yeasts and molds.
A. Groll, B. Rijnders, T. Walsh, J. Adler-Moore, R. Lewis, R. Brüggemann   +5 more
semanticscholar   +1 more source